Monday, January 18, 2021
Home Latest Pharma-News Harpoon Therapeutics and AbbVie Announce an elite worldwide option and license transaction...

Harpoon Therapeutics and AbbVie Announce an elite worldwide option and license transaction for HPN217 and Expand Existing Discovery Collaboration

Nov 21, 2019: Harpoon Therapeutics, Inc. a clinical-stage immunotherapy company developing a novel class of T cell engagers, and AbbVie Inc, a global biopharmaceutical company, announced an elite worldwide option and license transaction for HPN217, Harpoon’s B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC®), and an expansion of their existing discovery collaboration for up to six additional targets established by the two companies in October 2017.

The TriTAC platform produces novel T cell engagers targeting both solid tumors and hematologic malignancie.“Harpoon has built a unique and unshared  biologics platform that utilizes the patient’s own immune system to attack cancer. HPN217, targeting BCMA, is poised to proceed to clinical development for the treatment of multiple myeloma”,

- Advertisement -

Harpoon’s BCMA TriTAC combined with AbbVie’s development expertise, has the potential to generate innovative new medicines for patients with cancer. Under the terms of the license and option agreement, Harpoon granted to AbbVie an option to license worldwide exclusive rights to HPN217 through Phase 1/2 clinical trials. https://news.abbvie.com/news/press-releases/harpoon-therapeutics-and-abbvie-announce-licensing-and-option-collaboration-to-advance-hpn217-harpoons-bcma-targeting-tritac-and-expand-existing-discovery-collaboration.htm

LEAVE A REPLY

Please enter your comment!
Please enter your name here

3 − one =

Most Popular

GSK presents positive efficacy data of dostarlimab at ASCO Gastrointestinal Cancers Symposium

January 16, 2021: "GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid...

Bharat Biotech signs agreement with Precisa Medicamentos for supply of ‘COVAXIN™’ to Brazil

January 12, 2020: "Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Boehringer Ingelheim and Enara Bio join forces to discover Cancer Immunotherapies

January 12th, 2021: Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research...